###begin article-title 0
The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis
###end article-title 0
###begin p 1
This document may be redistributed and reused, subject to .
###end p 1
###begin title 2
Summary
###end title 2
###begin p 3
###xml 217 220 217 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;</italic>
###xml 434 444 432 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 602 612 599 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 196 211 <span type="species:ncbi:10090">transgenic mice</span>
###xml 217 220 <span type="species:ncbi:8790">Emu</span>
###xml 364 367 <span type="species:ncbi:8790">Emu</span>
###xml 434 437 <span type="species:ncbi:8790">Emu</span>
###xml 488 493 <span type="species:ncbi:9606">human</span>
###xml 602 605 <span type="species:ncbi:8790">Emu</span>
###xml 669 674 <span type="species:ncbi:9606">human</span>
###xml 738 743 <span type="species:ncbi:9606">human</span>
###xml 811 816 <span type="species:ncbi:9606">human</span>
Multiple myeloma (MM) evolves from a highly prevalent premalignant condition termed MGUS. The factors underlying the malignant transformation of MGUS are unknown. We report a MGUS/MM phenotype in transgenic mice with Emu-directed expression of the XBP-1 spliced isoform (XBP-1s), a factor governing unfolded protein/ER stress response and plasma-cell development. Emu-XBP-1s elicited elevated serum Ig and skin alterations. With age, Emu-xbp-1s transgenics develop features diagnostic of human MM, including bone lytic lesions and subendothelial Ig deposition. Furthermore, transcriptional profiles of Emu-xbp-1s lymphoid and MM cells show aberrant expression of known human MM dysregulated genes. The similarities of this model with the human disease, coupled with documented frequent XBP-1s overexpression in human MM, serve to implicate XBP-1s dysregulation in MM pathogenesis.
###end p 3
###begin title 4
SIGNIFICANCE
###end title 4
###begin p 5
###xml 0 869 0 869 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The significance of this work is underscored by the presence of MGUS in 1%&#8211;10% of adults, with 1%&#8211;3% progressing to MM annually. The genesis and progression of the disease are poorly understood, and the generation of a mouse model recapitulating many aspects of MGUS and MM provides an opportunity for the systematic dissection of the biological processes underlying disease progression. In particular, this genetically engineered MM-prone model enables validation of emerging MM-relevant (epi)genetic alterations and guides development of effective therapies targeting such validated rate-limiting aberrations. This genetic study and analysis of clinical samples suggest a pathogenetic role for sustained XBP-1s expression in the neoplastic transformation of plasma cells, indicating that chronic cellular stress contributes to the development of this common neoplasm.</bold>
###xml 219 224 <span type="species:ncbi:10090">mouse</span>
The significance of this work is underscored by the presence of MGUS in 1%-10% of adults, with 1%-3% progressing to MM annually. The genesis and progression of the disease are poorly understood, and the generation of a mouse model recapitulating many aspects of MGUS and MM provides an opportunity for the systematic dissection of the biological processes underlying disease progression. In particular, this genetically engineered MM-prone model enables validation of emerging MM-relevant (epi)genetic alterations and guides development of effective therapies targeting such validated rate-limiting aberrations. This genetic study and analysis of clinical samples suggest a pathogenetic role for sustained XBP-1s expression in the neoplastic transformation of plasma cells, indicating that chronic cellular stress contributes to the development of this common neoplasm.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 187 188 187 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">u</italic>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</italic>
###xml 579 602 579 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">Sirohi and Powles, 2006</xref>
###xml 738 787 738 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib25" ref-type="bibr">Bergsagel and Kuehl, 2005; Mitsiades et&#160;al., 2004</xref>
Multiple myeloma (MM) is a multifocal plasma-cell neoplasm characterized by serum monoclonal gammopathy and focal skeletal lesions. MM is preceded by a premalignant condition, monoclonal gammopathy of undetermined significance (MGUS), present in 1% of adults over the age of 25 and rising to 10% prevalence in individuals in their tenth decade. The genetic and environmental factors underlying MGUS and its progression to MM are largely unknown, although aberrant physiological responses to chronic immune stimulation are among the number of potential pathogenetic associations (Sirohi and Powles, 2006). MM remains incurable despite conventional high-dose chemotherapy and transplantation, translating into a median survival of 6 years (Bergsagel and Kuehl, 2005; Mitsiades et al., 2004).
###end p 7
###begin p 8
###xml 227 236 227 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cyclin D1</italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR3</italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMSET</italic>
###xml 256 261 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MAF</italic>
###xml 373 376 373 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ras</italic>
###xml 381 386 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR3</italic>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-MYC</italic>
###xml 429 437 429 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p16INK4A</italic>
###xml 439 447 439 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p18INK4C</italic>
###xml 449 453 449 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 459 463 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 528 580 528 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib17" ref-type="bibr">Bergsagel and Kuehl, 2005; Kuehl and Bergsagel, 2002</xref>
###xml 695 716 695 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4" ref-type="bibr">Carrasco et&#160;al., 2006</xref>
###xml 672 677 <span type="species:ncbi:9606">human</span>
###xml 744 749 <span type="species:ncbi:10090">mouse</span>
Extensive genomic analysis has revealed a large number of genes and loci associated with the development of MGUS and MM. Prominent cytogenetic events include chromosomal translocations involving Ig loci juxtaposed to the genes Cyclin D1, FGFR3, MMSET, and c-MAF, driving their overexpression. Additional genetic events typically associated with disease progression include Ras and FGFR3 activating mutations; c-MYC deregulation; p16INK4A, p18INK4C, TP53, and PTEN tumor suppressor gene inactivation; and chromosome 13 deletion (Bergsagel and Kuehl, 2005; Kuehl and Bergsagel, 2002). Recent genomic studies have provided evidence of many additional genetic lesions driving human MM pathogenesis (Carrasco et al., 2006). The availability of a MM mouse model would facilitate the identification and validation of these MM-relevant genes and provide a preclinical model for assessing therapeutic agents directed against such targets.
###end p 8
###begin p 9
###xml 267 305 267 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib5 bib28" ref-type="bibr">Cheung et&#160;al., 2004; Park et&#160;al., 2005</xref>
###xml 885 905 885 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10" ref-type="bibr">Garrett et&#160;al., 1997</xref>
###xml 1088 1108 1088 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib10" ref-type="bibr">Garrett et&#160;al., 1997</xref>
###xml 1237 1258 1237 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4" ref-type="bibr">Carrasco et&#160;al., 2006</xref>
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
###xml 559 564 <span type="species:ncbi:9606">human</span>
###xml 1178 1183 <span type="species:ncbi:9606">human</span>
###xml 1279 1284 <span type="species:ncbi:9606">human</span>
###xml 1573 1578 <span type="species:ncbi:9606">human</span>
Many experimental efforts to generate mouse models of B cell neoplasms, including MM, have typically involved targeted oncogene expression in the B cell compartment by transgenic and knockin approaches, alone or together with various tumor suppressor gene mutations (Cheung et al., 2004; Park et al., 2005). These modeling strategies have generally yielded B cell malignancies displaying immature phenotypes or plasmacytomas rather than classical MM. It is worth noting that mice do possess the inherent capacity to develop a spontaneous condition similar to human MGUS and MM, as evidenced by the capacity of the C57BL/KaLwRij strain to develop a plasma-cell dyscrasia, monoclonal gammopathy, and bone lytic lesions, albeit with late onset (after 2 years), low incidence (0.5%), and a propensity of these malignant plasma cells to home to lymphoid tissues other than the bone marrow (Garrett et al., 1997). Furthermore, the intravenous transplantation of these myeloma cells into syngeneic hosts has generated a single cell-line model that generates characteristic myeloma bone disease (Garrett et al., 1997). Along the lines of disease representation, it is worth noting that human MM consists of a minimum of four molecular subtypes (Carrasco et al., 2006) and that available human MM cell lines only partially represent these disease categories (D.R.C., G.T., and R.A.D., unpublished data). Together, these observations underscore the need for the continued development of genetic and cell-line models that capture the full range of genetic and biological diversity of human MM.
###end p 9
###begin p 10
###xml 795 815 795 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib29" ref-type="bibr">Reimold et&#160;al., 2001</xref>
###xml 1179 1238 1179 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15 bib20 bib33" ref-type="bibr">Iwakoshi et&#160;al., 2003b; Lee et&#160;al., 2002; Shen et&#160;al., 2001</xref>
###xml 1350 1366 1350 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21" ref-type="bibr">Lee et&#160;al., 2003</xref>
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
Based upon the above efforts to construct MM mouse models, we hypothesized that enforced B cell lineage-directed transgene expression of factors driving plasma-cell differentiation, alone or together with classical myeloma genes, would enhance the development of a MM-like disease. XBP-1 is a basic-region leucine zipper (bZIP) transcription factor of the CREB-ATF family and a major regulator of the unfolded protein response (UPR) and plasma-cell differentiation. XBP-1-deficient embryos die in utero from severe liver hypoplasia and resultant fatal anemia. Viable chimeras derived from XBP-1 null ES cells injected into Rag2 blastocysts reveal that XBP-1-deficient B cells proliferate and form germinal centers, yet there is a profound impairment in Ig secretion and absence of plasma cells (Reimold et al., 2001). XBP-1 is subject to alternative RNA processing, generating two mRNA transcripts encoding the same N-terminal DNA binding domain, but different C-terminal transactivation domains. The shorter spliced transcript, designated XBP-1s, possesses enhanced transactivation potential and stability relative to the product of the unspliced transcript, designated XBP-1u (Iwakoshi et al., 2003b; Lee et al., 2002; Shen et al., 2001). Thus, XBP-1u has no appreciable transactivation potential and may function as a dominant negative of XBP-1s (Lee et al., 2003).
###end p 10
###begin p 11
###xml 256 272 256 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib20" ref-type="bibr">Lee et&#160;al., 2002</xref>
###xml 321 366 317 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8 bib14" ref-type="bibr">Fujimoto et&#160;al., 2003; Iwakoshi et&#160;al., 2003a</xref>
###xml 454 473 450 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr">Munshi et&#160;al., 2004</xref>
###xml 547 563 543 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib39" ref-type="bibr">Wen et&#160;al., 1999</xref>
###xml 796 836 792 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6 bib26" ref-type="bibr">Davies et&#160;al., 2003; Munshi et&#160;al., 2004</xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 438 443 <span type="species:ncbi:9606">human</span>
###xml 689 694 <span type="species:ncbi:9606">human</span>
Recent studies have uncovered several functions for XBP-1 and have implicated XBP-1 overexpression in human carcinogenesis and tumor growth under hypoxic conditions. Specifically, elevated XBP-1 mRNA levels have been detected in hepatocellular carcinomas (Lee et al., 2002) and in primary ERalpha-positive breast tumors (Fujimoto et al., 2003; Iwakoshi et al., 2003a). With regard to MM, abundant expression of XBP-1 has been detected in human MM cells (Munshi et al., 2004) and can be induced by IL-6, a growth factor for malignant plasma cells (Wen et al., 1999). However, these studies did not provide definitive documentation of the particular XBP-1 isoform preferentially produced in human MM or provide insights into the pathophysiological relevance of these XBP-1 isoforms in MGUS and MM (Davies et al., 2003; Munshi et al., 2004).
###end p 11
###begin p 12
###xml 279 284 <span type="species:ncbi:10090">mouse</span>
###xml 416 421 <span type="species:ncbi:9606">human</span>
###xml 606 611 <span type="species:ncbi:9606">human</span>
###xml 738 744 <span type="species:ncbi:10090">murine</span>
In this study, we have explored the biological impact of sustained XBP-1s expression in the lymphoid system, anticipating that this genetic event would be a necessary component along with other MM-relevant oncogenes and tumor suppressor gene manipulations to generate a MM-prone mouse model. Unexpectedly, XBP-1s overexpression alone yielded a MGUS-MM disease bearing many features that are classic hallmarks of the human disease on the clinical, pathological, and molecular levels. These genetic observations were bolstered by an analysis of clinical samples documenting frequent XBP-1s overexpression in human MM samples relative to normal plasma cells, together implicating XBP-1s dysregulation in the genesis of this malignancy. This murine model of MGUS-MM provides a framework for understanding the molecular and biological mechanisms governing the genesis and progression of these common and enigmatic plasma-cell dyscrasias.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 20 25 <span type="species:ncbi:9606">Human</span>
XBP-1 Expression in Human Normal Plasma Cells and MM Cells
###end title 14
###begin p 15
###xml 141 181 141 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib6 bib26" ref-type="bibr">Davies et&#160;al., 2003; Munshi et&#160;al., 2004</xref>
###xml 455 463 455 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figure&#160;1</xref>
###xml 855 856 855 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1009 1018 1009 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figures 1</xref>
###xml 1070 1079 1070 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Figures 1</xref>
###xml 1221 1243 1221 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15" ref-type="bibr">Iwakoshi et&#160;al., 2003b</xref>
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
###xml 131 136 <span type="species:ncbi:9606">human</span>
###xml 409 414 <span type="species:ncbi:9606">human</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 1360 1365 <span type="species:ncbi:9606">human</span>
The unanticipated MM-prone condition in our mouse model (see below) and previous studies documenting increased XBP-1 expression in human MM (Davies et al., 2003; Munshi et al., 2004) prompted detailed XBP-1 expression studies in clinical samples. Tissue microarray immunohistochemical (TMA-IHC) and western blot assays were used to examine the relative levels and patterns of XBP-1 and its isoforms in normal human plasma cells, MGUS, and MM. As shown in Figure 1A, TMA-IHC analysis of bone marrow tissues derived from healthy donors and from MGUS and MM patients revealed low or undetectable XBP-1 protein expression in the plasma cells from ten healthy donors yet robust and widespread XBP-1 expression in 10/20 (50%) of MGUS and 50/70 (70%) of MM samples. Consistent with the IHC data, western blot analysis of protein extracts from 22 samples of CD138+ MM cells demonstrated a prominent shift toward increased XBP-1s expression in the majority of MM primary tumor samples relative to normal plasma cells (Figures 1B and 1C), a pattern also evident in MM cell lines (Figures 1C-1E). These correlative translational observations and the known capacity of XBP-1 to drive expression of MM-promoting factors such as IL-6 (Iwakoshi et al., 2003b and see below) prompts speculation that chronically increased levels of XBP-1s may contribute to the development of human MGUS and MM.
###end p 15
###begin title 16
###xml 14 24 14 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 14 17 <span type="species:ncbi:8790">Emu</span>
###xml 36 40 <span type="species:ncbi:10090">Mice</span>
Generation of Emu-xbp-1s Transgenic Mice Expressing XBP-1s in B Cells and Plasma Cells
###end title 16
###begin p 17
###xml 88 110 88 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14" ref-type="bibr">Iwakoshi et&#160;al., 2003a</xref>
###xml 186 192 186 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 253 254 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 252 254 252 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V<sub>H</sub></italic>
###xml 268 271 268 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;</italic>
###xml 297 305 295 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 345 355 343 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 434 440 431 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 564 572 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 684 692 681 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 37 42 <span type="species:ncbi:9606">human</span>
###xml 144 159 <span type="species:ncbi:10090">transgenic mice</span>
###xml 268 271 <span type="species:ncbi:8790">Emu</span>
###xml 291 294 <span type="species:ncbi:8790">Emu</span>
###xml 345 348 <span type="species:ncbi:8790">Emu</span>
On the basis of XBP-1s prominence in human MM and its potent transactivation potential (Iwakoshi et al., 2003a), we generated and characterized transgenic mice engineered to express the xbp-1s open reading frame under the control of the immunoglobulin VH promoter and Emu enhancer elements (Emu) (Figure 2A). Nine founders were obtained for the Emu-xbp-1s transgene, and Southern blot comparison of the endogenous (WT) and transgenic xbp-1s hybridization signals (TG) indicated transgene copy numbers ranging from approximately 1 to 15. The Southern blot shown in Figure 2B documents three of the nine founders in one representative litter derived from C57BL/6-microinjected oocytes (Figure 2B; other founder blots not shown). Two independent founder lines, S.7 and S.9, and their transgenic progeny, were propagated and used in this study.
###end p 17
###begin p 18
###xml 150 167 149 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">Kemp et&#160;al., 1980</xref>
###xml 177 187 176 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 361 369 359 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 475 485 473 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 553 559 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 638 646 635 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 715 716 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 775 783 772 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 857 867 854 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 932 940 928 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Figure&#160;2</xref>
###xml 37 40 <span type="species:ncbi:8790">Emu</span>
###xml 177 180 <span type="species:ncbi:8790">Emu</span>
###xml 475 478 <span type="species:ncbi:8790">Emu</span>
###xml 509 513 <span type="species:ncbi:10090">mice</span>
###xml 578 593 <span type="species:ncbi:10090">transgenic mice</span>
###xml 857 860 <span type="species:ncbi:8790">Emu</span>
In accord with the known capacity of Emu regulatory elements to drive transgene expression throughout B cell development, as well as in some T cells (Kemp et al., 1980), robust Emu-xbp-1s transgene expression was detected in the spleen, lymph nodes, thymus, and bone marrow of all nine founders, including S.7 and S.9 progeny, as determined by eGFP expression (Figure 2C, only S.7 shown). Analysis of purified splenic B cells using the pan-B cell marker B220 from 6-week-old Emu-xbp-1s transgenic and control mice showed increased levels of the spliced xbp-1s transcript in the transgenic mice correlating with transgene DNA copy number (Figure 2D and data not shown). Correspondingly, western blot analysis of B220+ splenic B cells confirmed elevated XBP-1s protein levels (Figure 2E), and anti-XBP-1 immunofluorescence showed stronger nuclear staining in Emu-xbp-1s transgenic B cells compared with nontransgenic B cell controls (Figure 2F).
###end p 18
###begin p 19
###xml 73 79 <span type="species:ncbi:10090">murine</span>
Together, these assays documented increased XBP-1s protein levels in the murine B lineage, enabling an in vivo analysis of the functional impact of enforced XBP-1s expression in B cell and plasma-cell compartments. To that end, all nine founders and the S.7 and S.9 progeny were assessed clinically using histological and flow cytometric analysis of lymphoid cells. While detailed phenotypic analysis described below focused on the two independent transgenic lines, S.7 and S.9, and their progeny, the same phenotype was observed in all nine founders.
###end p 19
###begin title 20
###xml 0 10 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 0 3 <span type="species:ncbi:8790">Emu</span>
###xml 22 26 <span type="species:ncbi:10090">Mice</span>
###xml 75 83 <span type="species:ncbi:9606">Patients</span>
Emu-xbp-1s Transgenic Mice Show Cutaneous and Renal Pathologies Resembling Patients with Chronic Plasma-Cell Disorders
###end title 20
###begin p 21
###xml 25 35 25 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 342 352 341 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 434 444 432 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 558 566 555 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 598 608 595 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 744 752 740 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 845 855 841 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 906 916 901 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1282 1283 1276 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1298 1299 1292 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</italic>
###xml 1312 1313 1306 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</italic>
###xml 1334 1335 1328 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 1358 1359 1352 1353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</italic>
###xml 1373 1390 1367 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">Dispenzieri, 2005</xref>
###xml 1393 1401 1387 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 25 28 <span type="species:ncbi:8790">Emu</span>
###xml 36 51 <span type="species:ncbi:10090">transgenic mice</span>
###xml 342 345 <span type="species:ncbi:8790">Emu</span>
###xml 434 437 <span type="species:ncbi:8790">Emu</span>
###xml 445 460 <span type="species:ncbi:10090">transgenic mice</span>
###xml 598 601 <span type="species:ncbi:8790">Emu</span>
###xml 609 624 <span type="species:ncbi:10090">transgenic mice</span>
###xml 845 848 <span type="species:ncbi:8790">Emu</span>
###xml 906 909 <span type="species:ncbi:8790">Emu</span>
###xml 1186 1194 <span type="species:ncbi:9606">patients</span>
Through 20 weeks of age, Emu-xbp-1s transgenic mice exhibited normal gross appearance, behavior, and weight curves. Histological surveys of the major organs, as well as flow cytometric profiles of spleens using the lymphoid cells markers CD3 and B220, did not demonstrate any abnormalities (data not shown). By approximately 40 weeks of age, Emu-xbp-1s transgenic animals began to manifest phenotypic changes in the skin and kidneys. Emu-xbp-1s transgenic mice exhibited an overall shortened life span resulting from severe cutaneous disease and/or myeloma (Figure 3A; see below). Sixty percent of Emu-xbp-1s transgenic mice developed hair loss and skin thickening around axillary and neck regions, whereas control littermates were unaffected (Figure 3B and data not shown). This cutaneous presentation was observed in all independently derived Emu-xbp-1s transgenic lines. Histological examination of the Emu-xbp-1s skin revealed epidermal thickening and some degree of hyperkeratosis with follicular plugging as well as dermal fibrosis with mild lymphoplasmacytic infiltrates and vascular hyperplasia. It is notable that these pathological changes are similar to those encountered in patients with specific autoimmune conditions and a rare plasma-cell disorder, termed POEMS (for polyneuropathy, organomegaly, endocrinopathy, serum monoclonal protein, and skin lesions) (Dispenzieri, 2005) (Figure 3B).
###end p 21
###begin p 22
###xml 13 23 13 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 104 112 103 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 229 237 228 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 364 372 363 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 650 670 649 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13" ref-type="bibr">Herrera et&#160;al., 2004</xref>
###xml 989 997 988 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Figure&#160;3</xref>
###xml 1215 1224 1214 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S1</xref>
###xml 1233 1250 1232 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Supplemental Data</xref>
###xml 1379 1399 1378 1398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib18" ref-type="bibr">Kyle and Gertz, 1990</xref>
###xml 1426 1436 1425 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 13 16 <span type="species:ncbi:8790">Emu</span>
###xml 24 39 <span type="species:ncbi:10090">transgenic mice</span>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 1109 1117 <span type="species:ncbi:9606">patients</span>
###xml 1360 1365 <span type="species:ncbi:9606">human</span>
###xml 1369 1377 <span type="species:ncbi:9606">patients</span>
###xml 1426 1429 <span type="species:ncbi:8790">Emu</span>
By 40 weeks, Emu-xbp-1s transgenic mice also showed renal pathology, including tubular cast deposition (Figure 3C, white arrows) and glomerular changes characterized by mesangial widening and deposition of PAS-positive material (Figure 3C, yellow arrows). Transmission electron microscopy showed mesangial and subendothelial deposition of electron-dense material (Figure 3C, black arrows). These renal lesions are similar to the pathologic manifestations present in human MM and other plasma-cell disorders with systemic chronic Ig overproduction and accumulation of light chains (light-chain cast nephropathy), paraproteins, and other Ig fragments (Herrera et al., 2004). To assess whether these lesions were Ig deposits, immunofluorescence with antibodies specific for light- and heavy-chain Ig was performed. Nonspecific trapping of light- and heavy-chain Ig was present and consisted of either polyclonal heavy and light chains or clonal IgM or IgG heavy chain and kappa light chains (Figure 3D and data not shown). To determine whether amyloid depositions were present, a feature occasionally seen in MM patients, Congo red stains performed across several tissues and independent cell lines were negative (see Figure S1A in the Supplemental Data available with this article online) suggesting that amyloid deposition, which is observed rarely (5%-15%) in human MM patients (Kyle and Gertz, 1990), is not a feature of the Emu-xbp-1s disease model.
###end p 22
###begin title 23
###xml 81 91 81 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 81 84 <span type="species:ncbi:8790">Emu</span>
###xml 103 107 <span type="species:ncbi:10090">Mice</span>
Altered Proliferative Potential of Splenic B Cells and Hypergammaglobulinemia in Emu-xbp-1s Transgenic Mice
###end title 23
###begin p 24
###xml 93 103 93 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 267 276 266 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S1</xref>
###xml 393 403 392 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 424 433 422 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 503 504 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 518 528 514 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 550 551 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 585 595 578 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 676 677 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 756 757 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 905 906 889 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 911 912 895 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 916 917 900 901 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1007 1008 987 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1011 1013 991 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 1017 1018 997 998 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1077 1087 1053 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1105 1114 1080 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 1151 1152 1126 1127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1209 1219 1184 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1270 1271 1244 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1275 1276 1249 1250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1378 1379 1348 1349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1383 1384 1353 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1418 1421 1388 1391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">low</sup>
###xml 1425 1426 1395 1396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1431 1441 1401 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1467 1476 1436 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 93 96 <span type="species:ncbi:8790">Emu</span>
###xml 104 119 <span type="species:ncbi:10090">transgenic mice</span>
###xml 393 396 <span type="species:ncbi:8790">Emu</span>
###xml 518 521 <span type="species:ncbi:8790">Emu</span>
###xml 585 588 <span type="species:ncbi:8790">Emu</span>
###xml 596 611 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1077 1080 <span type="species:ncbi:8790">Emu</span>
###xml 1088 1103 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1209 1212 <span type="species:ncbi:8790">Emu</span>
###xml 1220 1235 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1431 1434 <span type="species:ncbi:8790">Emu</span>
Serial gross, histological, and flow cytometric examination of the spleen and bone marrow of Emu-xbp-1s transgenic mice showed alterations after 20-40 weeks of age. The spleens appeared slightly enlarged and showed increased plasma cells around periarterial sheaths (Figure S1B, arrows). Flow cytometric analysis showed unaltered total numbers of T cell (CD3) and B cell (B220) populations in Emu-xbp-1s transgenic spleens (Figure S2A). The total number of mononuclear cells between wild-type (8.05 x 107 +/- 0.5) and Emu-xbp-1s transgenic (7.95 x 107 +/- 1.5) spleens did not differ. Emu-xbp-1s transgenic mice at 40 weeks of age showed a slightly enlarged population of CD23+ cells (49.1% +/- 3.9% versus 40.2% +/- 0.1%) and a reciprocal decrease in CD23- cells (43.3% +/- 1.5% versus 53.4% +/- 1.9%). We observed a trend toward increased number of precursor and mature follicular cells T2/M cells (CD23+/CD21+/IgM+ cells) (34.1% +/- 1.2% versus 26.4% +/- 1.4%) as well as marginal zone (MZ) B cells (CD23-IgMhiCD21+ cells) (3% +/- 0.1% versus 1% +/- 0.0%) in the spleens of Emu-xbp-1s transgenic mice (Figure S2B). In addition, the fraction of B220+ cells in the bone marrow was significantly increased in Emu-xbp-1s transgenic mice with an increase in the mature IgM+B220+ B cell population (17.2% +/- 1.2% versus 10.8% +/- 0.2%) and a relative decrease of pro-B cells (B220+CD43+) in relation to pre-B cells (B220lowCD43-) in Emu-xbp-1s transgenic bone marrows (Figure S2B).
###end p 24
###begin p 25
###xml 212 232 212 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib31" ref-type="bibr">Shaffer et&#160;al., 2004</xref>
Overall, these studies reinforce the view that enforced XBP-1s expression has an impact beyond the well-established role of this transcription factor in the terminal differentiation of B cells into plasma cells (Shaffer et al., 2004).
###end p 25
###begin p 26
###xml 166 176 166 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 194 202 193 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Figure&#160;4</xref>
###xml 276 284 275 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Figure&#160;4</xref>
###xml 313 323 312 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 744 745 742 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">4</xref>
###xml 751 752 749 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
###xml 755 763 753 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S1</xref>
###xml 166 169 <span type="species:ncbi:8790">Emu</span>
###xml 177 192 <span type="species:ncbi:10090">transgenic mice</span>
###xml 313 316 <span type="species:ncbi:8790">Emu</span>
###xml 324 339 <span type="species:ncbi:10090">transgenic mice</span>
Consistent with the above observation of expanded B cell compartment, plasma immunoglobulin levels of both IgM and IgG types by ELISA were significantly increased in Emu-xbp-1s transgenic mice (Figure 4A). Serum protein electrophoresis (SPEP) revealed presence of an M spike (Figure 4A, arrow) in the majority of Emu-xbp-1s transgenic mice, but not in control littermates as early as 20 weeks of age-a feature that increased in frequency and magnitude with advancing age (data not shown). Notably, these serum changes were associated in some cases with bone lytic lesions and increased numbers of plasma cells in the bone marrow that varied from 5%-30% of the total bone marrow cellularity compared with <5% for nontransgenic controls (Figures 4B and 5A; Table S1).
###end p 26
###begin p 27
###xml 52 62 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 110 111 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</italic>
###xml 123 124 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</italic>
###xml 135 136 134 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 154 173 153 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib38" ref-type="bibr">Tusher et&#160;al., 2001</xref>
###xml 306 316 305 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 394 404 392 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 515 523 512 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 546 593 543 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17 bib31" ref-type="bibr">Kuehl and Bergsagel, 2002; Shaffer et&#160;al., 2004</xref>
###xml 774 784 771 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 887 896 883 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 52 55 <span type="species:ncbi:8790">Emu</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 306 309 <span type="species:ncbi:8790">Emu</span>
###xml 394 397 <span type="species:ncbi:8790">Emu</span>
###xml 447 452 <span type="species:ncbi:9606">human</span>
###xml 774 777 <span type="species:ncbi:8790">Emu</span>
On the molecular level, transcriptome comparison of Emu-xbp-1s and nontransgenic B cells (n = 5 mice each) by significance analysis of microarrays (SAM) (Tusher et al., 2001) revealed 1119 genes that were differentially expressed (false discovery rate [FDR] = 1%), 808 upregulated and 311 downregulated in Emu-xbp-1s B cells versus nontransgenic B cells. Among the genes selectively altered in Emu-xbp-1s B cells are those with known relevance to human MM pathogenesis, such as Cyclin D1, Cyclin D2, MAF, and MAFB (Figure 6A and data not shown) (Kuehl and Bergsagel, 2002; Shaffer et al., 2004). Given the role of these genes in cell-cycle regulation, proliferative potential of wild-type and transgenic B cells were examined ex vivo. Consistent with the molecular changes, Emu-xbp-1s transgenic B cells exhibited increased incorporation of thymidine relative to nontransgenic controls (Figure S2C, p = 0.002). Enhanced proliferative potential of the transgenic B cells was also observed in response to stimulation with B cell activators CD40, anti-IgM, or CD40 together with anti-IgM (data not shown).
###end p 27
###begin p 28
###xml 34 54 34 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib3" ref-type="bibr">Calvano et&#160;al., 2005</xref>
###xml 499 508 499 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S3</xref>
###xml 756 766 756 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 816 825 815 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S2</xref>
###xml 666 670 <span type="species:ncbi:10090">mice</span>
###xml 756 759 <span type="species:ncbi:8790">Emu</span>
###xml 767 782 <span type="species:ncbi:10090">transgenic mice</span>
Knowledge-based pathway analysis (Calvano et al., 2005) of the 1119 SAM-significant genes also revealed alterations in several pathways (p < 0.0001). A notable MM-relevant pathway that was prominently altered is IL-6, where the two components of the IL-6 receptor, IL-6R and gp130, show significant upregulation, along with three members of the CEBP family, CEBPA, CEBPB, and CEBPD, in addition to several downstream targets of these transcriptional factors, such as ALOX5, LITAF, MMP8, and IFITM3 (Figure S3A). Prompted by this observation, we examined the level of serum IL-6, to determine whether a more general dysregulation of this pathway was present in these mice. Consistent with the activation of this pathway, serum IL-6 levels were increased in Emu-xbp-1s transgenic mice relative to control littermates (Figure S2C, p < 0.005), while the plasma levels of other cytokines, including IL-2, IL-4, IL-5, and IL-10, were unchanged (data not shown).
###end p 28
###begin p 29
Taken together, the phenotypic and molecular analyses of transgenic and nontransgenic B cells uncovered cancer-relevant biological consequences of XBP-1s overexpression, including B cell hyperproliferation and IL-6 activation, both of which are plausible mechanisms capable of driving plasma-cell transformation.
###end p 29
###begin title 30
###xml 33 43 33 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 33 36 <span type="species:ncbi:8790">Emu</span>
###xml 55 59 <span type="species:ncbi:10090">Mice</span>
Spontaneous MGUS and MM in Aging Emu-xbp-1s Transgenic Mice
###end title 30
###begin p 31
###xml 72 82 72 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 216 226 215 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 305 315 303 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 553 561 550 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S1</xref>
###xml 627 637 624 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 848 849 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">4</xref>
###xml 860 861 856 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
###xml 864 872 860 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Table S1</xref>
###xml 1043 1051 1039 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 1088 1091 1084 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IgH</italic>
###xml 1149 1157 1145 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 1248 1273 1244 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr">Kuehl and Bergsagel, 2002</xref>
###xml 1288 1298 1284 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1416 1424 1411 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Figure&#160;5</xref>
###xml 1657 1666 1652 1661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eu-xbp-1s</italic>
###xml 72 75 <span type="species:ncbi:8790">Emu</span>
###xml 216 219 <span type="species:ncbi:8790">Emu</span>
###xml 227 242 <span type="species:ncbi:10090">transgenic mice</span>
###xml 305 308 <span type="species:ncbi:8790">Emu</span>
###xml 316 331 <span type="species:ncbi:10090">transgenic mice</span>
###xml 627 630 <span type="species:ncbi:8790">Emu</span>
###xml 638 653 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1232 1237 <span type="species:ncbi:9606">human</span>
###xml 1288 1291 <span type="species:ncbi:8790">Emu</span>
###xml 1667 1682 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1729 1734 <span type="species:ncbi:9606">human</span>
The above constellation of findings prompted detailed analysis of aging Emu-xbp-1s and nontransgenic controls for evidence of MGUS and/or MM. As early as 40 weeks of age, a classical MGUS profile emerged only in the Emu-xbp-1s transgenic mice. Between 11 and 20 months of age, approximately 26% (9/35) of Emu-xbp-1s transgenic mice showed a clonal M spike in the serum and expanded populations of clonal plasma cells in the bone marrow (<10% of the total bone marrow mononuclear cells), without bone lytic lesions and consistent with a pattern of MGUS (Table S1; data not shown). Between 14 and 24 months of age, 26% (8/35) of Emu-xbp-1s transgenic mice progressed to frank MM as defined by a clonal M spike in the serum, bone marrow consisting of >10% of clonal plasma cells, and associated bone lytic lesions on radiographic examination (Figures 4A, 4B, and 5A; Table S1; and data not shown). Clonality of the MM cells was evidenced by IHC of immunoglobulin heavy and light-chain subtype expression, as performed in the clinical laboratory (Figure 5A), and by Southern blot analysis of IgH gene rearrangement analysis in bone marrow plasma cells (Figure 5B). In accord with the concept of a postgerminal center cell derivation of human MM cells (Kuehl and Bergsagel, 2002), some of the Emu-xbp-1s MMs showed evidence of somatic hypermutation between the body of the 3' JH4 region of rearranged variable (V) genes (Figure 5C). Neither MGUS nor MM was detected in control littermates at any age, indicating that XBP-1s overexpression promotes the development of a condition similar to MGUS and MM. In summary, spontaneous progression from MGUS to MM in the Eu-xbp-1s transgenic mice clinically mirrors disease progression in the human.
###end p 31
###begin p 32
###xml 111 121 111 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 255 265 254 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 320 330 318 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 494 504 491 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 757 767 753 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 783 793 778 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1109 1144 1103 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12 bib27" ref-type="bibr">He et&#160;al., 2004; Novak et&#160;al., 2004</xref>
###xml 1190 1200 1184 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1455 1524 1448 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4 bib19 bib25" ref-type="bibr">Carrasco et&#160;al., 2006; Le Gouill et&#160;al., 2004; Mitsiades et&#160;al., 2004</xref>
###xml 1634 1643 1627 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S3</xref>
###xml 1686 1696 1679 1688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1882 1891 1874 1883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figures 6</xref>
###xml 2158 2227 2150 2219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4 bib19 bib25" ref-type="bibr">Carrasco et&#160;al., 2006; Le Gouill et&#160;al., 2004; Mitsiades et&#160;al., 2004</xref>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 111 114 <span type="species:ncbi:8790">Emu</span>
###xml 171 176 <span type="species:ncbi:10090">mouse</span>
###xml 255 258 <span type="species:ncbi:8790">Emu</span>
###xml 320 323 <span type="species:ncbi:8790">Emu</span>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 494 497 <span type="species:ncbi:8790">Emu</span>
###xml 757 760 <span type="species:ncbi:8790">Emu</span>
###xml 783 786 <span type="species:ncbi:8790">Emu</span>
###xml 1167 1172 <span type="species:ncbi:9606">human</span>
###xml 1190 1193 <span type="species:ncbi:8790">Emu</span>
###xml 1439 1444 <span type="species:ncbi:9606">human</span>
###xml 1686 1689 <span type="species:ncbi:8790">Emu</span>
###xml 1744 1749 <span type="species:ncbi:9606">human</span>
###xml 1825 1831 <span type="species:ncbi:10090">murine</span>
###xml 1864 1869 <span type="species:ncbi:9606">human</span>
###xml 2035 2040 <span type="species:ncbi:9606">human</span>
###xml 2143 2148 <span type="species:ncbi:9606">human</span>
To further compare this mouse model with the human disease, we performed transcriptome profiling to define the Emu-xbp-1s myeloma signature. Transcriptome analyses in the mouse identified 708 genes overexpressed and 1784 genes downregulated (FDR = 1%) in Emu-xbp-1s MM cells relative to B cells from young neoplasm-free Emu-xbp-1s mice. Supporting a pathogenetic role for XBP-1s overexpression in the myeloma genesis in this model, several known MM genes that were dysregulated in premalignant Emu-xbp-1s B cells exhibited similar patterns of alterations in XBP-1s MM cells, including Cyclin D1, MAF, CEBPA, CEBPB, CEBPD, IL6ST (upregulated), and FOS (downregulated). Conversely, some notable MM signature genes were found to be selectively dysregulated in Emu-xbp-1s MM, but not in Emu-xbp-1s B cells, in line with the need for additional spontaneously occurring cooperating events as reflected in the long latency of the MM phenotype. Among such genes selectively upregulated in the tumors were APRIL and BAFF, both of which have been found to be overexpressed in various B cell malignancies, including MM (He et al., 2004; Novak et al., 2004). However, unlike the human counterpart, the Emu-xbp-1s MM transcriptome revealed evidence of prominent activation of proapoptotic tumor suppression mechanisms characterized by downregulation of the antiapoptotic genes, MCL1 and BCL2, which are typically upregulated or amplified in aggressive human MM cases (Carrasco et al., 2006; Le Gouill et al., 2004; Mitsiades et al., 2004). Interestingly, MCL1 and BCL2 were not downregulated in hyperproliferative premalignant transgenic B cells (Figure S3B and data not shown). Consistent with the Emu-xbp-1s gene expression pattern and in contrast to the human disease, we documented a marked increase in apoptosis and proliferation in murine MM samples relative to those in human MM samples (Figures 6B and 6C). Such observations gain added significance in light of the observation that MCL1 maps to a region of gene amplification in aggressive human MM primary tumors and prompt speculation that MCL1 and BCL2 play critical roles in the progression of human myeloma (Carrasco et al., 2006; Le Gouill et al., 2004; Mitsiades et al., 2004)-a theory that can now be tested in this genetic model system.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 59 64 <span type="species:ncbi:9606">human</span>
In this study, we provide genetic evidence and correlative human data supporting a role for the differentiation and unfolded protein/ER stress response factor X box binding protein-1 spliced isoform (XBP-1s) in the development of MGUS and MM. Our molecular and phenotypic analyses of the XBP-1s-driven myeloma model implicate the chronic ER stress response in MM pathogenesis.
###end p 34
###begin title 35
###xml 25 30 <span type="species:ncbi:10090">Mouse</span>
###xml 40 45 <span type="species:ncbi:9606">Human</span>
A Genetically Engineered Mouse Model of Human MM
###end title 35
###begin p 36
###xml 8 18 8 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 560 570 559 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 888 927 886 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7 bib32" ref-type="bibr">Dispenzieri, 2005; Shahidi et&#160;al., 1995</xref>
###xml 8 11 <span type="species:ncbi:8790">Emu</span>
###xml 295 300 <span type="species:ncbi:9606">human</span>
###xml 347 352 <span type="species:ncbi:10090">mouse</span>
###xml 369 374 <span type="species:ncbi:9606">human</span>
###xml 423 428 <span type="species:ncbi:10090">mouse</span>
###xml 433 438 <span type="species:ncbi:9606">human</span>
###xml 514 519 <span type="species:ncbi:9606">human</span>
###xml 560 563 <span type="species:ncbi:8790">Emu</span>
###xml 732 737 <span type="species:ncbi:10090">mouse</span>
###xml 747 753 <span type="species:ncbi:9606">humans</span>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
In this Emu-xbp-1s transgenic model, enforced XBP-1s expression in the B cell compartment enhances B cell proliferative potential and activates known MM-relevant pathways, leading to the development of MGUS and MM disease possessing many of the molecular, cellular, and clinical features of the human condition. As in other genetically engineered mouse (GEM) models of human diseases, some differences do exist between the mouse and human conditions, particularly in the levels of genome instability. In addition, human MM is predominantly of IgG isotype, but Emu-xbp-1s MGUS and MM cases are either the IgG isotype (50%) or the IgM isotype (50%). Another difference is the prevalence of dermatitis and splenic plasmacytosis in the mouse that, in humans, are more commonly encountered in patients with atypical plasma-cell malignancies such as the POEMS syndrome and Castleman's disease (Dispenzieri, 2005; Shahidi et al., 1995).
###end p 36
###begin p 37
###xml 336 346 336 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 767 792 766 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr">Kuehl and Bergsagel, 2002</xref>
###xml 999 1026 998 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30" ref-type="bibr">Sebastian and Johnson, 2006</xref>
###xml 1145 1155 1144 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-XBP-1s</italic>
###xml 1418 1440 1416 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib9" ref-type="bibr">Gagliardi et&#160;al., 2003</xref>
###xml 1486 1508 1484 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib36" ref-type="bibr">Takeshita et&#160;al., 2004</xref>
###xml 1573 1583 1571 1580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1624 1634 1621 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 1677 1681 1673 1677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a pr</italic>
###xml 1693 1694 1689 1690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</italic>
###xml 1702 1703 1698 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</italic>
###xml 1880 1890 1876 1885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 2115 2150 2110 2145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib12 bib27" ref-type="bibr">He et&#160;al., 2004; Novak et&#160;al., 2004</xref>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 95 101 <span type="species:ncbi:9606">humans</span>
###xml 313 318 <span type="species:ncbi:9606">human</span>
###xml 336 339 <span type="species:ncbi:8790">Emu</span>
###xml 552 557 <span type="species:ncbi:9606">human</span>
###xml 757 762 <span type="species:ncbi:9606">human</span>
###xml 1145 1148 <span type="species:ncbi:8790">Emu</span>
###xml 1466 1471 <span type="species:ncbi:9606">human</span>
###xml 1573 1576 <span type="species:ncbi:8790">Emu</span>
###xml 1614 1619 <span type="species:ncbi:9606">human</span>
###xml 1624 1627 <span type="species:ncbi:8790">Emu</span>
###xml 1880 1883 <span type="species:ncbi:8790">Emu</span>
At the same time, there are remarkable similarities between the disease phenotypes in mice and humans. These include progression from MGUS to MM accompanied by bone marrow involvement with clonal plasma cells, serum M spike, bone lytic lesions, and Ig deposition in the kidney, all classical defining features of human MM. Molecularly, Emu-xbp-1s MM exhibited dysregulation of several signature MM genes and pathways. For example, expression alteration of genes such as Cyclin D1, gp130, and MAF parallel the dysregulation of these genes identified in human MM cells, which are variously driven by recurrent chromosomal translocations, gene amplification, and/or transcriptional mechanisms and represent essential elements in the genesis and progression of human MM (Kuehl and Bergsagel, 2002). The proliferation effect induced by IL-6 is mediated by the PI3K and MAPK pathways and through the activation of CEBPB. Given the known role of the CEBP family of transcription factors in carcinogenesis (Sebastian and Johnson, 2006), the strong overexpression of CEBPB, as well as CEBPA and CEBPD, may contribute to the strong proliferative drive of Emu-XBP-1s B transgenic cells that, through the acquisition of additional genetic/epigenetic lesions, could promote the development of MGUS and MM. Additionally, CEBPB exerts an inhibitory activity toward the AP1 complex, at both the expression and transcriptional levels (Gagliardi et al., 2003), demonstrated also in a human MM cell line (Takeshita et al., 2004), that may be responsible for the low JUN and FOS levels in the Emu-xbp-1s B cells. Also, in accord with human MM, Emu-xbp-1s MM cells exhibit overexpression of APRIL (a proliferation-inducing ligand). APRIL is a member of the tumor necrosis family of ligands, which also includes B lymphocyte stimulator/B cell activating factor (BlyS/BAFF, which is also upregulated in Emu-xbp-1s MM cells), and these factors have been shown to serve essential prosurvival roles in normal and malignant B lymphocytes. Increased expression of APRIL or BlyS have been reported in various B cell malignancies, including MM (He et al., 2004; Novak et al., 2004).
###end p 37
###begin p 38
###xml 147 157 147 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-XBP-1s</italic>
###xml 514 579 513 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4 bib19 bib35" ref-type="bibr">Carrasco et&#160;al., 2006; Le Gouill et&#160;al., 2004; Spets et&#160;al., 2002</xref>
###xml 622 632 621 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 641 649 639 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 774 784 772 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 829 837 826 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Figure&#160;6</xref>
###xml 1075 1092 1072 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib40" ref-type="bibr">Zhan et&#160;al., 2002</xref>
###xml 1275 1284 1272 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="app2" ref-type="sec">Figure&#160;S3</xref>
###xml 1453 1463 1450 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 147 150 <span type="species:ncbi:8790">Emu</span>
###xml 158 163 <span type="species:ncbi:10090">mouse</span>
###xml 195 200 <span type="species:ncbi:9606">human</span>
###xml 292 297 <span type="species:ncbi:9606">human</span>
###xml 353 358 <span type="species:ncbi:10090">mouse</span>
###xml 363 368 <span type="species:ncbi:9606">human</span>
###xml 504 509 <span type="species:ncbi:9606">human</span>
###xml 622 625 <span type="species:ncbi:8790">Emu</span>
###xml 774 777 <span type="species:ncbi:8790">Emu</span>
###xml 785 790 <span type="species:ncbi:10090">mouse</span>
###xml 811 816 <span type="species:ncbi:9606">human</span>
###xml 1065 1073 <span type="species:ncbi:9606">patients</span>
###xml 1212 1220 <span type="species:ncbi:9606">patients</span>
###xml 1392 1397 <span type="species:ncbi:9606">human</span>
###xml 1453 1456 <span type="species:ncbi:8790">Emu</span>
Taken together, these cross-species multilevel comparisons, spanning from molecular to organismal levels, provide a measure of validation that the Emu-XBP-1s mouse represents a relevant model of human MM, suggesting its utility in the study of pathways known or presumed to be altered in the human disease. In this regard, molecular characterization of mouse and human MM has implicated two antiapoptotic genes, MCL1 and BCL2, in MM progression. MCL1 and BCL2 are commonly amplified and overexpressed in human MM (Carrasco et al., 2006; Le Gouill et al., 2004; Spets et al., 2002); however, they were downregulated in the Emu-xbp-1s tumors (Figure 6B), but not in premalignant B cells. This pattern of expression is consistent with the observed increase in apoptosis in the Emu-xbp-1s mouse MM when compared to human MM samples (Figure 6D), suggesting that active proapoptotic mechanisms may be acting to constrain the MM phenotype in this model. Moreover, analysis of published data comparing the expression level of plasma cells from healthy donors, MGUS, and MM patients (Zhan et al., 2002) indeed shows that only a subset of MM samples have significantly higher MCL1 levels than healthy donors, whereas MGUS patients and normal donors present comparable MCL1 expression (Figure S3B). These observations prompt speculation that MCL1 plays an especially critical role in the progression of human MM and motivate additional genetic modeling studies in Emu-xbp-1s system to formally test the role of MCL1 in MM progression.
###end p 38
###begin p 39
###xml 221 231 221 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 578 588 577 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 978 988 976 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 221 224 <span type="species:ncbi:8790">Emu</span>
###xml 578 581 <span type="species:ncbi:8790">Emu</span>
###xml 685 690 <span type="species:ncbi:9606">human</span>
###xml 978 981 <span type="species:ncbi:8790">Emu</span>
###xml 989 1004 <span type="species:ncbi:10090">transgenic mice</span>
Given the relatively long latency and low penetrance in the appearance of MGUS and MM in this model, it stands to reason that additional genetic lesions and pathway dysregulations are needed to develop MGUS and MM in the Emu-xbp-1s system. Indeed, several hallmark genes and pathways linked to MM pathogenesis are altered at the premalignant B cell level, for example Cyclin D1, Cyclin D2, MAF, and MAFB, providing a proliferation impetus to precursor B cells and plasma cells. However, other genes are consistently dysregulated specifically in the transition to MM, but not in Emu-xbp-1s B cells or in the nontransgenic B cells such as BAFF, APRIL, and several genes associated in MM human studies with a high degree of proliferation and poor prognosis (TOP2A, BIRC5, CCNB2, NEK2, AURKA, BUB1, CDC2, and CDCA1; data not shown), suggesting that other genetic and/or epigenetic additional lesions are needed to drive the progression into MGUS and furthermore into MM. Therefore, Emu-xbp-1s transgenic mice constitute a valuable tool for in vivo testing of genetic lesions capable of inducing MGUS and full-blown MM, on the backdrop of a paraphysiological increase in plasma-cell number.
###end p 39
###begin title 40
Role of XBP-1s and ER Stress Response in MM Pathogenesis
###end title 40
###begin p 41
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XBP-1</italic>
###xml 189 237 189 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1 bib4" ref-type="bibr">Bergsagel and Kuehl, 2005; Carrasco et&#160;al., 2006</xref>
###xml 288 293 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XBP-1</italic>
###xml 681 704 665 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib23" ref-type="bibr">Ma and Hendershot, 2001</xref>
###xml 793 810 777 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11" ref-type="bibr">Gass et&#160;al., 2004</xref>
###xml 929 944 913 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib22" ref-type="bibr">Li et&#160;al., 2005</xref>
###xml 1057 1080 1041 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">Sirohi and Powles, 2006</xref>
###xml 3 9 <span type="species:ncbi:9606">humans</span>
###xml 172 177 <span type="species:ncbi:9606">human</span>
###xml 1346 1351 <span type="species:ncbi:9606">human</span>
In humans, the XBP-1 gene has not been implicated in MM pathogenesis because it does not reside in a region targeted from chromosomal amplification and/or translocation in human MM tumors (Bergsagel and Kuehl, 2005; Carrasco et al., 2006). However, there is evidence that genes affecting XBP-1 processing are subject to genetic changes, potentially leading to epigenetic dysregulation of the XBP-1 network in MM. For example, the activating transcription factor 6alpha (ATF6alpha), S1P, and S2P proteases, as well as ER transmembrane protein kinase and endoribonuclease inositol-requiring enzyme-1alpha (IREalpha), are all members of the proximal transducers of the mammalian UPR (Ma and Hendershot, 2001). Furthermore, it is known that XBP-1 activation/overexpression is a downstream target (Gass et al., 2004) of the ER stress response pathway, which is perturbed in the setting of viral infections and inflammatory responses (Li et al., 2005). This gains significance in light of the long suspected link between autoimmunity and/or inflammation with MM (Sirohi and Powles, 2006) as well as our genetic observations that sustained XBP-1s overexpression alone is capable of driving MM development, raising the intriguing possibility that this physiological stress response could have unwanted "side effects" that are of fundamental relevance to human MM pathogenesis. In particular, we speculate that the long-term survival of plasma cells and MGUS cells may require enhanced activation of XBP-1s to handle the high levels of antibody production and/or environmental stresses. In this scenario, enhanced activation of XBP-1s may lead to chronic IL-6 production and activation of other MM-relevant circuits, ultimately driving progression along the MGUS-MM continuum.
###end p 41
###begin p 42
###xml 23 33 23 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 23 26 <span type="species:ncbi:8790">Emu</span>
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 152 157 <span type="species:ncbi:9606">human</span>
###xml 236 241 <span type="species:ncbi:9606">human</span>
In summary, we propose Emu-xbp-1s transgenic mouse as a relevant model of human MGUS and MM. Additionally, this genetic study, coupled with analysis of human samples, highlights the potential importance of XBP-1s in the pathogenesis of human MGUS and MM.
###end p 42
###begin title 43
Experimental Procedures
###end title 43
###begin title 44
###xml 11 15 <span type="species:ncbi:10090">Mice</span>
Transgenic Mice
###end title 44
###begin p 45
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 23 42 23 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2" ref-type="bibr">Calfon et&#160;al., 2002</xref>
###xml 840 846 836 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
###xml 209 214 <span type="species:ncbi:9606">human</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
###xml 901 916 <span type="species:ncbi:10090">transgenic mice</span>
The mouse xbp-1s cDNA (Calfon et al., 2002) was cloned into the pBluescript II vector, which also contains a 1 kb fragment of the mouse variable chain enhancer and promoter (pEmu) and a 1.6 Kb fragment of the human beta-globin gene to provide introns and the polyadenylation signal sequence. The transgene also encoded farnesylated eGFP coding sequences behind an IRES element. The transgenic encoding sequences were released from the vector by BssHII digestion and purified by zonal sucrose gradient centrifugation and microinjected into C57BL/6 oocytes. Transgene-positive mice were mated with C57BL/6 mice to generate transgenic and control littermates on the same inbred C57BL/6 background for all subsequent analyses. Screening of the transgenic founders and copy-number analysis were done using Southern blot analysis with the entire xbp-1s cDNA as a radiolabeled probe. Subsequent screening of transgenic mice was done by PCR analysis using a set of GFP-specific primers (5'-ACGTAAACGG CCACAAGTTC-3' and 5'-AAGTCGTGCT TCATGTG-3'). All animal experiments were approved by and conform to the standards of the Institutional Animal Care and Use Committee at the DFCI.
###end p 45
###begin title 46
###xml 10 11 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 16 21 <span type="species:ncbi:9606">Human</span>
Mouse B220+ and Human Plasma-Cell CD138+ Isolation, RNA Preparation, Expression Profiling, and Reverse Transcription PCR
###end title 46
###begin p 47
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 293 310 293 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib40" ref-type="bibr">Zhan et&#160;al., 2002</xref>
###xml 649 650 649 650 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1289 1307 1289 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib37" ref-type="bibr">Tonon et&#160;al., 2005</xref>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 234 239 <span type="species:ncbi:10090">mouse</span>
###xml 245 250 <span type="species:ncbi:9606">human</span>
B220+ splenic B cells were isolated using magnetic microbeads from Miltenyi Biotec. Plasma cells were isolated from human bone marrow mononuclear cells from healthy donors (Cambrex BioScience) using immunomagnetic bead selection with mouse anti-human CD138 monoclonal antibodies as described (Zhan et al., 2002), except that we used LS MACS separation columns (Miltenyi Biotec) and before incubating the bone marrow mononuclear cells to CD138-coated magnetic beads, we removed contaminating histiocytes and macrophages by preloading and washing out the cells in the magnetic columns and field. Total RNA was isolated from control and transgenic B220+ splenic mononuclear cells or myeloma tumors using TRIzol Reagent. Affymetrix 430 2.0 arrays were hybridized at the DFCI Microarray Core Facility. CEL files were obtained using Affymetrix Microarray Suite 5.0 software. The DNA Chip Analyzer (dChip) was used to normalize all CEL files to a baseline array with overall median intensity, and the model-based expression (perfect match minus mismatch) was used to compute the expression values. The same data were also analyzed using the Ingenuity Pathways Analysis (Ingenuity Systems) software. For SAM analysis, probes were included in the analysis if they fulfilled the following criteria (Tonon et al., 2005): (1) SD > 0.3; (2) >20% of samples with expression value > 100; (3) >20% of samples with presence call.
###end p 47
###begin p 48
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 232 237 <span type="species:ncbi:9606">Women</span>
###xml 262 267 <span type="species:ncbi:9606">human</span>
The primers for xbp-1s cDNA were 5'-ACACGCTTGG GAATGGACAC-3' and 5'-CCATGGGAAG ATGTTCTGGG-3', which flanked the spliced region in xbp-1s. PCR products were analyzed on a 3% agarose gel. The Institutional Review Board of Brigham and Women's Hospital approved the human research studies, and all subjects provided written informed consent approving use of their samples for research purposes.
###end p 48
###begin title 49
X-Ray, Histopathology, and Immunohistochemistry
###end title 49
###begin p 50
###xml 421 426 <span type="species:ncbi:10090">mouse</span>
###xml 433 439 <span type="species:ncbi:9986">rabbit</span>
###xml 516 519 <span type="species:ncbi:10116">rat</span>
###xml 525 530 <span type="species:ncbi:10090">mouse</span>
###xml 553 556 <span type="species:ncbi:10116">rat</span>
###xml 562 567 <span type="species:ncbi:10090">mouse</span>
###xml 587 592 <span type="species:ncbi:10090">mouse</span>
###xml 598 603 <span type="species:ncbi:9606">human</span>
###xml 604 609 <span type="species:ncbi:10090">mouse</span>
###xml 825 829 <span type="species:ncbi:9925">goat</span>
###xml 835 840 <span type="species:ncbi:10090">mouse</span>
###xml 966 977 <span type="species:ncbi:3704">horseradish</span>
Bone X-ray was performed using Faxitron X-ray Specimen Radiographic System and Kodak X-OMAT-TL films. Tissues were fixed, processed, sectioned, and stained with hematoxylin-eosin (H&E) or PAS for light microscopy examination by routine methods. Spine and femurs were additionally treated for 1 hr in decalcifying solution (Fisher Scientific). Immunohistochemistry was performed according to standard procedures. The anti-mouse XBP-1 rabbit polyclonal antibody (M-186) was obtained from Santa Cruz Biotechnology. The rat anti-mouse CD45R/B220 (RA3-6B2), rat anti-mouse CD138 (281-2), and mouse anti-human/mouse Ki-67 (B56) monoclonal antibodies were obtained from BD Biosciences. The primary antibodies were visualized with the corresponding biotinylated antibody coupled to streptavidin-peroxidase complex (Vector Labs). The goat anti-mouse polyclonal antibodies for immunoglobulin heavy chains IgA, IgM, IgG, and kappa or lambda light chains were all conjugated to horseradish peroxidase and obtained from Southern Biotechnology. All antibodies, conditions, and reactivities were tested in positive control slides. Apoptag assay (Chemicon) was performed on tissue slides according to the manufacturer's protocols.
###end p 50
###begin title 51
Cytospin Preparation, Immunofluorescence, and Transmission Electron Microscopy
###end title 51
###begin p 52
###xml 139 144 <span type="species:ncbi:10090">mouse</span>
###xml 151 157 <span type="species:ncbi:9986">rabbit</span>
###xml 248 254 <span type="species:ncbi:9986">rabbit</span>
###xml 302 307 <span type="species:ncbi:10090">mouse</span>
###xml 373 379 <span type="species:ncbi:10090">murine</span>
###xml 431 435 <span type="species:ncbi:9925">goat</span>
###xml 455 460 <span type="species:ncbi:10090">mouse</span>
###xml 679 683 <span type="species:ncbi:9925">goat</span>
###xml 689 694 <span type="species:ncbi:10090">mouse</span>
###xml 853 859 <span type="species:ncbi:10090">murine</span>
Cytospin slides were prepared using a cytocentrifuge (Thermo Shandon), fixed 2 min at RT in acetone:methanol (1:1), and stained using anti-mouse XBP-1 rabbit polyclonal antibody as a primary antibody followed by visualization with fluorescein anti-rabbit IgG or directly labeled using fluorescein anti-mouse IgG (both from Vector Labs). Immunofluorescence was performed on murine kidney samples using fluorescein (FITC)-conjugated goat antibodies against mouse immunoglobulins IgA, IgG, IgM, kappa light chain, and lambda light chain (Southern Biotechnology). For kidney immunofluorescence, tissue sections were fixed in glutaraldehyde and processed using fluorescein-conjugated goat anti-mouse antibodies for immunoglobulin heavy chains IgA, IgM, IgG, and light chains kappa or lambda from Southern Biotechnologies. Transmission electron microscopy of murine kidney samples was performed using standard procedures after fixation in Karnovsky's media.
###end p 52
###begin title 53
Flow Cytometry
###end title 53
###begin p 54
###xml 540 541 540 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Red blood cells were removed from single-cell suspensions from spleens, thymuses, and bone marrow by ammonium chloride treatment (Sigma). Cells were then washed in 3% BSA in PBS and stained for 30 min on ice with a combination of the following antibodies: B220-FITC, B220-PE, CD3-PE, CD138-PE, CD8-FITC, CD4-PE, CD21-FITC, CD43-FITC (BD Biosciences), IgD-FITC, IgM-APC, and CD23-PE (eBioscience). Cells were washed twice and analyzed on a FACScalibur machine (Becton Dickinson) using cell Quest software (Becton Dickinson). An average of 105 cells was recorded in each case.
###end p 54
###begin title 55
In Vitro Proliferation
###end title 55
###begin p 56
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 269 270 266 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
B220+cells (2 x 105) were plated in triplicate in 96-well plates before stimulation with LPS (10 mug/ml, Sigma), anti-mouse CD40 (1 mug/ml, BD Pharmigen), anti-IgM (10 mug/ml, BD Pharmigen), or CD40 and anti-IgM. After 16 hr of stimulation, the cells were pulsed with [3H]thymidine for the final 16 hr of growth before thymidine incorporation was measured by a scintillation counter. Results are expressed as mean +/- SD of triplicate cultures. Similar results were obtained in three independent experiments.
###end p 56
###begin title 57
Clonality and Hypermutation Analysis
###end title 57
###begin p 58
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IgH</italic>
###xml 173 217 173 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib4 bib24" ref-type="bibr">Carrasco et&#160;al., 2006; McDonald et&#160;al., 2003</xref>
Southern analysis for clonotypic IgH rearrangements and hypermutation analysis of the 3' JH4 region of rearranged variable (V) genes were performed as described previously (Carrasco et al., 2006; McDonald et al., 2003).
###end p 58
###begin title 59
Western Blots
###end title 59
###begin p 60
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 214 219 <span type="species:ncbi:10090">mouse</span>
###xml 226 232 <span type="species:ncbi:9986">rabbit</span>
###xml 579 590 <span type="species:ncbi:3704">horseradish</span>
###xml 613 617 <span type="species:ncbi:9925">goat</span>
###xml 623 629 <span type="species:ncbi:9986">rabbit</span>
###xml 638 643 <span type="species:ncbi:10090">mouse</span>
Whole-cell extracts from B220+ splenocytes single- or snap-frozen tissues were prepared, electroblotted onto PVDF membranes (Amersham), and probed with primary antibodies according to standard procedures. The anti-mouse XBP-1 rabbit polyclonal antibody (M-186), anti-beta-actin-HRP (C-11), c-FOS (4-10G), and anti-GFP (B-2) antibodies were from Santa Cruz. Cyclin D1 (DCS6), c-JUN (60A8), and caspase-3 (8G10) antibodies were obtained from Cell Signaling; MCL1 (Rockland), PAX5 (Chemicon), and BCL2 (3F11) antibodies from BD Biosciences were also used. Following incubation with horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse secondary antibody (Pierce), bound immunoglobulins were detected using ECL detection solutions (Pierce). For consecutive staining with different antisera, membranes were stripped with Restore western blot stripping buffer (Pierce). Anti-beta-actin immunoreactivity is included as a loading control.
###end p 60
###begin title 61
Chemokine, Immunoglobulin, and Paraprotein Determination
###end title 61
###begin p 62
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
Serum chemokine and immunoglobulin concentrations were measured by ELISA using the Beadlyte mouse multicytokine detection system from Upstate. Elevated levels of IL-6 were confirmed using the Quantikine immunoassay from R&D Systems. All samples were analyzed in triplicate. Paraproteins (M spikes, extra gradients) were detected using Paragon SPE electrophoresis kit (Beckman Coulter Inc).
###end p 62
###begin title 63
Microarray Data
###end title 63
###begin p 64
The raw data for expression profiling and the CEL files are available at Gene Expression Omnibus () with accession number GSE6980.
###end p 64
###begin title 65
Supplemental Data
###end title 65
###begin p 66
The Supplemental Data include three supplemental figures and one supplemental table and can be found with this article online at .
###end p 66
###begin title 67
Supplemental Data
###end title 67
###begin p 68
###xml 0 66 0 66 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="69">Document S1. Three Supplemental Figures and One Supplemental Table</title>
###xml 0 66 0 66 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="69">Document S1. Three Supplemental Figures and One Supplemental Table</title></caption>
###xml 66 66 66 66 <media xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/>
###xml 0 66 0 66 <supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="mmc1"><caption><title textid="69">Document S1. Three Supplemental Figures and One Supplemental Table</title></caption><media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material>
Document S1. Three Supplemental Figures and One Supplemental Table
###end p 68
###begin title 69
Document S1. Three Supplemental Figures and One Supplemental Table
###end title 69
###begin title 70
Accession Numbers
###end title 70
###begin p 71
The raw data for expression profiling and the CEL files are available at Gene Expression Omnibus () with accession number GSE6980.
###end p 71
###begin title 72
Acknowledgments
###end title 72
###begin p 73
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 107 112 <span type="species:ncbi:9606">human</span>
We wish to thank to Michelle Neptune of the DFCI Transgenic Core Facility, Tai Yu-Tzu for providing CD138+ human myeloma cells, David Ron for providing the xbp-1s cDNA, Frederic Alt for providing the pEmu transgenic expression vector, and John Quackenbush for advice on the expression data analysis. We also thank Hongkai Ji (Department of Statistics, Harvard University) and Wing H. Wong (Department of Statistics, Stanford University). This work was supported by U01 CA84313 and the LeBow Fund to Cure Myeloma (R.A.D., G.T., and K.C.A.). R.A.D. is supported by the Robert A. and Renee E. Belfer Institute for Innovative Cancer Science and is an American Cancer Society Research Professor and Ellison Medical Foundation Senior Scholar. D.R.C. is supported by a Mentored Clinician Scientist Award (K08AG0103) and is a Sidney Kimmel Foundation Scholar. G.T. is supported by the International Myeloma Foundation, a Brian D. Novis Research Award, and a Multiple Myeloma SPORE Career Development Award and is a Special Fellow of the Leukemia and Lymphoma Society. K.C.A. is supported by NIH R01-CA50947, PO1-CA78378, and P50-CA10070 and the Doris Duke Distinguished Clinical Research Scientist Award.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
Molecular pathogenesis and a consequent classification of multiple myeloma
###end article-title 75
###begin article-title 76
IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA
###end article-title 76
###begin article-title 77
###xml 53 59 <span type="species:ncbi:9606">humans</span>
A network-based analysis of systemic inflammation in humans
###end article-title 77
###begin article-title 78
###xml 100 108 <span type="species:ncbi:9606">patients</span>
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients
###end article-title 78
###begin article-title 79
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice
###end article-title 79
###begin article-title 80
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis
###end article-title 80
###begin article-title 81
POEMS Syndrome
###end article-title 81
###begin article-title 82
###xml 35 40 <span type="species:ncbi:9606">human</span>
Upregulation and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers
###end article-title 82
###begin article-title 83
Opposing roles of C/EBPbeta and AP-1 in the control of fibroblast proliferation and growth arrest-specific gene expression
###end article-title 83
###begin article-title 84
###xml 2 8 <span type="species:ncbi:10090">murine</span>
###xml 18 23 <span type="species:ncbi:9606">human</span>
A murine model of human myeloma bone disease
###end article-title 84
###begin article-title 85
Stressed-out B cells? Plasma cell differentiation and the unfolded protein response
###end article-title 85
###begin article-title 86
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL
###end article-title 86
###begin article-title 87
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia
###end article-title 87
###begin article-title 88
The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response
###end article-title 88
###begin article-title 89
Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1
###end article-title 89
###begin article-title 90
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
Expression of the immunoglobulin C mu gene in mouse T and B lymphoid and myeloid cell lines
###end article-title 90
###begin article-title 91
Multiple myeloma: Evolving genetic events and host interactions
###end article-title 91
###begin article-title 92
Systemic amyloidosis
###end article-title 92
###begin article-title 93
Mcl-1 regulation and its role in multiple myeloma
###end article-title 93
###begin article-title 94
IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response
###end article-title 94
###begin article-title 95
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
###end article-title 95
###begin article-title 96
Tula hantavirus triggers pro-apoptotic signals of ER stress in Vero E6 cells
###end article-title 96
###begin article-title 97
The unfolding tale of the unfolded protein response
###end article-title 97
###begin article-title 98
###xml 23 27 <span type="species:ncbi:10090">mice</span>
129-derived strains of mice are deficient in DNA polymerase iota and have normal immunoglobulin hypermutation
###end article-title 98
###begin article-title 99
Focus on multiple myeloma
###end article-title 99
###begin article-title 100
Identification of genes modulated in multiple myeloma using genetically identical twin samples
###end article-title 100
###begin article-title 101
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival
###end article-title 101
###begin article-title 102
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice
###end article-title 102
###begin article-title 103
Plasma cell differentiation requires the transcription factor XBP-1
###end article-title 103
###begin article-title 104
Stop and go: Anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta
###end article-title 104
###begin article-title 105
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation
###end article-title 105
###begin article-title 106
Castleman's disease
###end article-title 106
###begin article-title 107
###xml 93 103 <span type="species:ncbi:238774|species:ncbi:386067|species:ncbi:147878|species:ncbi:193182|species:ncbi:313250|species:ncbi:323266|species:ncbi:315362|species:ncbi:148887|species:ncbi:124036|species:ncbi:48798|species:ncbi:529401|species:ncbi:314391|species:ncbi:646318|species:ncbi:254962|species:ncbi:323047|species:ncbi:287681|species:ncbi:269614|species:ncbi:103475|species:ncbi:114942|species:ncbi:212608|species:ncbi:457136|species:ncbi:227469|species:ncbi:449387|species:ncbi:551876|species:ncbi:248142|species:ncbi:252961|species:ncbi:466267|species:ncbi:119832|species:ncbi:228196|species:ncbi:316080|species:ncbi:217897|species:ncbi:109099|species:ncbi:328850|species:ncbi:266263|species:ncbi:348465|species:ncbi:181251|species:ncbi:6239|species:ncbi:320029|species:ncbi:293163|species:ncbi:4853|species:ncbi:160529|species:ncbi:292745|species:ncbi:368875|species:ncbi:323318|species:ncbi:209968|species:ncbi:405608|species:ncbi:480533">C. elegans</span>
Complementary signaling pathways regulate the unfolded protein response and are required for C. elegans development
###end article-title 107
###begin article-title 108
Epidemiology and outcomes research for MGUS, myeloma and amyloidosis
###end article-title 108
###begin article-title 109
Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: Regulation during interleukin-6(IL-6)-induced growth and survival
###end article-title 109
###begin article-title 110
###xml 34 39 <span type="species:ncbi:9606">human</span>
Transcriptional regulation of the human TLR9 gene
###end article-title 110
###begin article-title 111
###xml 36 41 <span type="species:ncbi:9606">human</span>
High-resolution genomic profiles of human lung cancer
###end article-title 111
###begin article-title 112
Significance analysis of microarrays applied to the ionizing radiation response
###end article-title 112
###begin article-title 113
###xml 110 115 <span type="species:ncbi:9606">human</span>
Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells
###end article-title 113
###begin article-title 114
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
###end article-title 114
###begin p 115
Predominance of the Spliced Form of XBP-1 over the Unspliced Form in MM Primary Tumors
###end p 115
###begin p 116
###xml 171 179 <span type="species:ncbi:9606">patients</span>
(A) Immunohistochemical analysis for XBP-1 expression was performed on bone marrow tissue microarrays from healthy (PCs) donors (n = 10) and MGUS (n = 20) and MM (n = 70) patients. Representative results are shown. CD138 is stained in red, and XBP-1 is stained in brown. Scale bars, 50 mum (10 mum in insets).
###end p 116
###begin p 117
(B) Plasma cells were isolated from the bone marrow of healthy donors (lanes 1 and 2) and MM primary tumors (lanes 3-24) using CD138 magnetic beads, and total protein extract (40 mug per lane) was subjected to western blot analysis using anti-XBP-1 antibodies.
###end p 117
###begin p 118
(C)Total protein extract (20 mug) from CD138 purified normal plasma cells (PC), MM primary tumors (MM), the MM1S MM cell line treated with 10 mug/ml of Tunicamycin (TM) and untreated (NT) for 4 hr, and 293T cells lentivirally infected with XBP-1s (Pos. Control) were electrophoresed and subjected to western blot analysis using XBP-1 antibodies. Protein loading was assessed by Ponceau staining and Ig light-chain immunostaining.
###end p 118
###begin p 119
(D) Total protein extracts (40 mug per lane) from CD138-purified normal plasma cells (PC) and MM cell lines were subjected to western blot analysis using XBP-1 antibodies.
###end p 119
###begin p 120
(E) Immunofluorescence analysis of XBP-1 expression on MM1S cell line. Scale bars, 50 mum.
###end p 120
###begin p 121
###xml 35 45 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 35 38 <span type="species:ncbi:8790">Emu</span>
###xml 57 61 <span type="species:ncbi:10090">Mice</span>
Generation and Characterization of Emu-xbp-1s Transgenic Mice
###end p 121
###begin p 122
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 128 129 128 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
###xml 143 146 <span type="species:ncbi:8790">Emu</span>
(A) Transgenic construct. The xbp-1s cDNA encoding the spliced form of mouse XBP-1 was cloned downstream of the immunoglobulin VH promoter and Emu enhancer (pEmu) elements. In addition to expressing XBP-1s, the transgene also encodes a farnesylated eGFP coding sequence behind an IRES element.
###end p 122
###begin p 123
###xml 32 42 32 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 181 187 180 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1s</italic>
###xml 207 212 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1</italic>
###xml 32 35 <span type="species:ncbi:8790">Emu</span>
###xml 43 58 <span type="species:ncbi:10090">transgenic mice</span>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
(B) Southern blot genotyping of Emu-xbp-1s transgenic mice was done on EcoRI-digested genomic tail DNA and hybridized with a radiolabeled probe encoding 5' sequences from the mouse xbp-1s cDNA. Note genomic xbp-1 sequences (WT) as well as transgenic sequences (TG). Only three of nine founders are shown.
###end p 123
###begin p 124
###xml 187 202 <span type="species:ncbi:10090">transgenic mice</span>
(C) High levels of transgene expression in spleen, lymph nodes, and thymus as evaluated by eGFP western blot analysis on total organ protein extracts isolated from 6-week-old control and transgenic mice.
###end p 124
###begin p 125
###xml 64 74 64 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 197 202 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xbp-1</italic>
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
###xml 64 67 <span type="species:ncbi:8790">Emu</span>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
(D) RT-PCR analysis using mRNA from purified mouse B cells from Emu-xbp-1s transgenic (S.1, S.7, S.9) and control (WT) mice. The 171 bp and 145 bp DNA fragments correspond to unspliced and spliced xbp-1 mRNAs, respectively.
###end p 125
###begin p 126
###xml 29 39 29 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 100 101 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 29 32 <span type="species:ncbi:8790">Emu</span>
(E) Western blot analysis of Emu-xbp-1s transgenic (S.1, S.7, and S.9) and control (WT) splenic B220+ B cells.
###end p 126
###begin p 127
###xml 52 62 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 52 55 <span type="species:ncbi:8790">Emu</span>
(F) Immunofluorescence staining of control (WT) and Emu-xbp-1s transgenic splenic B cells. Scale bars, 10 mum. The genomic DNA, mRNA, and protein extracts were isolated from 6-week-old transgenic and control littermates.
###end p 127
###begin p 128
###xml 41 51 41 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 41 44 <span type="species:ncbi:8790">Emu</span>
###xml 63 67 <span type="species:ncbi:10090">Mice</span>
Survival, Skin, and Renal Alterations in Emu-xbp-1s Transgenic Mice
###end p 128
###begin p 129
###xml 56 66 56 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 157 167 156 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 56 59 <span type="species:ncbi:8790">Emu</span>
###xml 67 82 <span type="species:ncbi:10090">transgenic mice</span>
###xml 157 160 <span type="species:ncbi:8790">Emu</span>
(A) Disease-free survival (lack of skin alterations) in Emu-xbp-1s transgenic mice. Statistically significant differences (p < 0.0001) were detected between Emu-xbp-1s transgenic and control littermates.
###end p 129
###begin p 130
###xml 24 34 24 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 162 172 161 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 24 27 <span type="species:ncbi:8790">Emu</span>
###xml 35 50 <span type="species:ncbi:10090">transgenic mice</span>
###xml 162 165 <span type="species:ncbi:8790">Emu</span>
###xml 173 188 <span type="species:ncbi:10090">transgenic mice</span>
(B) Skin alterations in Emu-xbp-1s transgenic mice. Note loss of hair and skin thickening in axillary region. Histological H&E sections showing dermal changes in Emu-xbp-1s transgenic mice. Note epidermal thickening, dermal fibrosis, and vascular proliferation (insets). Scale bars, 1.0 cm (left panel), 50 mum (middle and left panels), and 20 mum (insets).
###end p 130
###begin p 131
###xml 60 70 60 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 60 63 <span type="species:ncbi:8790">Emu</span>
###xml 71 86 <span type="species:ncbi:10090">transgenic mice</span>
(C) Renal tissue sections from 40-week-old control (WT) and Emu-xbp-1s transgenic mice were stained with H&E, PAS, or subjected to electron microscopic analysis (EM). White arrows, tubular protein deposition; yellow arrows, mesangial protein deposition; black arrows, subendothelial deposits. Scale bars, 50 mum (H&E), 20 mum (PAS), 0.1 mum (EM).
###end p 131
###begin p 132
###xml 93 103 93 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 93 96 <span type="species:ncbi:8790">Emu</span>
###xml 186 191 <span type="species:ncbi:10090">mouse</span>
(D) Glomerular immunoglobulin deposition. Serial frozen renal sections from control (WT) and Emu-xbp-1s tissue sections were analyzed by immunofluorescence using specific antibodies for mouse immunoglobulin kappa and lambda light chains, as well as IgA, IgG, and IgM heavy chains. Scale bars, 20 mum.
###end p 132
###begin p 133
###xml 87 97 87 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 87 90 <span type="species:ncbi:8790">Emu</span>
###xml 109 113 <span type="species:ncbi:10090">Mice</span>
Hypergammaglobulinemia, Bone Marrow Plasmacytic Infiltrates, and Bone Lytic Lesions in Emu-xbp-1s Transgenic Mice
###end p 133
###begin p 134
###xml 55 65 55 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 118 128 117 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 258 268 256 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 339 349 336 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 467 477 463 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 55 58 <span type="species:ncbi:8790">Emu</span>
###xml 66 81 <span type="species:ncbi:10090">transgenic mice</span>
###xml 118 121 <span type="species:ncbi:8790">Emu</span>
###xml 129 144 <span type="species:ncbi:10090">transgenic mice</span>
###xml 258 261 <span type="species:ncbi:8790">Emu</span>
###xml 269 284 <span type="species:ncbi:10090">transgenic mice</span>
###xml 339 342 <span type="species:ncbi:8790">Emu</span>
###xml 350 365 <span type="species:ncbi:10090">transgenic mice</span>
###xml 467 470 <span type="species:ncbi:8790">Emu</span>
###xml 478 493 <span type="species:ncbi:10090">transgenic mice</span>
(A) Marked elevation of serum immunoglobulin levels in Emu-xbp-1s transgenic mice. Serum plasma from control (WT) and Emu-xbp-1s transgenic mice were measured by ELISA, protein serum electrophoresis, and densitometry. Note the presence of M spike (arrow) in Emu-xbp-1s transgenic mice. Representative bone marrow biopsies from control and Emu-xbp-1s transgenic mice were analyzed by light microscopy (H&E) to reveal increased plasma-cell infiltrates in the marrow of Emu-xbp-1s transgenic mice.
###end p 134
###begin p 135
###xml 26 36 26 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 83 93 82 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 26 29 <span type="species:ncbi:8790">Emu</span>
###xml 37 52 <span type="species:ncbi:10090">transgenic mice</span>
###xml 83 86 <span type="species:ncbi:8790">Emu</span>
###xml 94 109 <span type="species:ncbi:10090">transgenic mice</span>
(B) Bone lytic lesions in Emu-xbp-1s transgenic mice. Femurs from control (WT) and Emu-xbp-1s transgenic mice were dissected to detect the presence of bone lytic lesions by X-ray (white arrows) and immunohistochemical analysis (black arrow). B, cortical bone. Scale bars 20 mum (upper panel), 0.5 cm (lower panels, femur), 0.25 cm (insets), 50 mum (CD138).
###end p 135
###begin p 136
###xml 65 75 65 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 65 68 <span type="species:ncbi:8790">Emu</span>
###xml 87 91 <span type="species:ncbi:10090">Mice</span>
Evidence of Clonality and Hypermutation of Expressed Ig Genes in Emu-xbp-1s Transgenic Mice
###end p 136
###begin p 137
(A) IHC analysis of plasma-cell clonality from bone marrow biopsies. Scale bars, 50 mum (10 mum in insets).
###end p 137
###begin p 138
###xml 86 96 86 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 86 89 <span type="species:ncbi:8790">Emu</span>
###xml 330 335 <span type="species:ncbi:10090">mouse</span>
(B) Southern blot analysis for clonotypic immunoglobulin heavy-chain rearrangement in Emu-xbp-1s myeloma tumors. High-molecular-weight DNA was isolated from snap-frozen control or myeloma marrows, digested with EcoRI restriction enzyme, and hybridized with a  1.9 BamHI-EcoRI genomic probe fragment downstream and adjacent to the mouse heavy-chain locus JH segment. GL denotes the germline band.
###end p 138
###begin p 139
###xml 121 131 121 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 121 124 <span type="species:ncbi:8790">Emu</span>
(C) DNA sequence chromatograms of PCR products detect mutations in the 3' JH4 region of rearranged variable (V) genes in Emu-xbp-1s tumors.
###end p 139
###begin p 140
###xml 27 37 27 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 27 30 <span type="species:ncbi:8790">Emu</span>
Altered Gene Expression of Emu-xbp-1s B Cells and Tumor Plasma Cells and Increased Apoptosis of Tumor Plasma Cells
###end p 140
###begin p 141
###xml 225 244 225 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib38" ref-type="bibr">Tusher et&#160;al., 2001</xref>
(A) Ingenuity analysis showing altered expression of Cyclin D1 and c-MAF in myeloma tumors. In red are significantly overexpressed genes and in green are downregulated genes. Color intensity is proportional to the SAM score (Tusher et al., 2001).
###end p 141
###begin p 142
(B) Western blot analysis showing activation of caspase-3, as well as decreased c-JUN, c-FOS, MCL1, and BCL2 in transgenic B cells and MM tumors as compared to wild-type samples.
###end p 142
###begin p 143
###xml 81 91 81 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E&#956;-xbp-1s</italic>
###xml 81 84 <span type="species:ncbi:8790">Emu</span>
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
###xml 143 148 <span type="species:ncbi:9606">human</span>
(C) IHC showing increased apoptosis (Apoptag) and proliferation index (Ki-67) in Emu-xbp-1s myeloma primary mouse tumors (PT) as compared with human myeloma tumors (hMM). Scale bars, 50 mum (20 mum in insets).
###end p 143

